International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 118-129
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |
Patients’ and Physicians’ Preferences for Approaches to Bone Metastases Treatment in Turkey
Francesca GATTA1, Juan Marcos GONZALEZ2, Gulnihal ERTUGRUL3, Yi QIAN4, A Brett HAUBER2, Joshua POSNER2, Berna OKSUZOGLU5, Jorge ARELLANO4
1Amgen (Europe) GmbH, Zug, SWITZERLAND
2RTI Health Solutions, Research Triangle Park, NC, USA
3Amgen Turkey, Istanbul, TURKEY
4Amgen Inc., Thousand Oaks, CA, USA
5Ankara Oncology Training and Research Hospital, Department of Medical Oncology, Ankara, TURKEY
Keywords: Bone-targeted agents, Bone metastases, Discrete-choice experiment, Patient preference, Physician preference, Skeletal-related event
Bone metastases and associated skeletal-related events (SREs) are common in patients with advanced breast, lung, and prostate cancer. Bone-targeted agents (BTAs) are available for the treatment of bone metastases, but little is known about patients’ and physicians’ preferences for the various attributes of these agents. We evaluated preferences for BTAs used to prevent SREs among patients with bone metastases and physicians involved in treating such patients in Turkey. Participants completed an online discretechoice experiment survey of 10 questions, choosing between pairs of hypothetical treatment profiles, defined by five BTA attributes: time to first SRE, time to worsening of pain, annual risk of osteonecrosis of the jaw (ONJ), annual risk of renal impairment, and administration regimen. The analysis included 91 patients and 99 physicians. Both groups rated annual risk of renal impairment, time to worsening of pain, and time to first SRE as the most important BTA attributes. For patients, the preference weights for all levels of these attributes were significantly different, whereas for physicians, preference weights were significantly different for all levels except time to a 2-point increase in “Brief Pain Inventory” score by 6 months or 10 months. Annual risk of ONJ was judged by patients and physicians to be the least important of the BTA attributes. This study adds to the information available on the preferences of patients and physicians for BTAs and provides useful data to aid clinicians in decision-making by understanding the treatment goals that are important to patients in Turkey.
Francesca GATTA1, Juan Marcos GONZALEZ2, Gulnihal ERTUGRUL3, Yi QIAN4, A Brett HAUBER2, Joshua POSNER2, Berna OKSUZOGLU5, Jorge ARELLANO4
1Amgen (Europe) GmbH, Zug, SWITZERLAND
2RTI Health Solutions, Research Triangle Park, NC, USA
3Amgen Turkey, Istanbul, TURKEY
4Amgen Inc., Thousand Oaks, CA, USA
5Ankara Oncology Training and Research Hospital, Department of Medical Oncology, Ankara, TURKEY
Keywords: Bone-targeted agents, Bone metastases, Discrete-choice experiment, Patient preference, Physician preference, Skeletal-related event
Bone metastases and associated skeletal-related events (SREs) are common in patients with advanced breast, lung, and prostate cancer. Bone-targeted agents (BTAs) are available for the treatment of bone metastases, but little is known about patients’ and physicians’ preferences for the various attributes of these agents. We evaluated preferences for BTAs used to prevent SREs among patients with bone metastases and physicians involved in treating such patients in Turkey. Participants completed an online discretechoice experiment survey of 10 questions, choosing between pairs of hypothetical treatment profiles, defined by five BTA attributes: time to first SRE, time to worsening of pain, annual risk of osteonecrosis of the jaw (ONJ), annual risk of renal impairment, and administration regimen. The analysis included 91 patients and 99 physicians. Both groups rated annual risk of renal impairment, time to worsening of pain, and time to first SRE as the most important BTA attributes. For patients, the preference weights for all levels of these attributes were significantly different, whereas for physicians, preference weights were significantly different for all levels except time to a 2-point increase in “Brief Pain Inventory” score by 6 months or 10 months. Annual risk of ONJ was judged by patients and physicians to be the least important of the BTA attributes. This study adds to the information available on the preferences of patients and physicians for BTAs and provides useful data to aid clinicians in decision-making by understanding the treatment goals that are important to patients in Turkey.
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |